Abstract
Esophageal squamous cell carcinoma (ESCC) shows a remarkable variation in incidence which is not fully explained by known lifestyle and environmental risk factors. It has been speculated that an unknown exogenous exposure(s) could be responsible. Here we combine the fields of mutational signature analysis with cancer epidemiology to study 552 ESCC genomes from eight countries with varying incidence rates. The mutational profiles of ESCC were similar across all countries studied. Associations between specific mutational signatures and ESCC risk factors were identified for tobacco, alcohol, opium and germline variants, with modest impacts on mutation burden. We find no evidence of a mutational signature indicative of an exogenous exposure capable of explaining the differences in ESCC incidence. APOBEC associated mutational signatures SBS2 and SBS13 were present in 88% and 91% of cases respectively and accounted for a quarter of the mutation burden on average, indicating that activation of APOBEC is a crucial step in ESCC tumor development.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by a Cancer Grand Challenges Mutographs team award funded by Cancer Research UK [C98/A24032] and Wellcome grant reference 206194. The work was also partly funded by R21CA191965 (Eldoret), Wereld Kanker Onderzoek Fonds (WKOF) / World Cancer Research Fund (2018/1795) and IARC Section of Environment and Radiation. The work of R.C.C.P. reported in this paper was undertaken during the tenure of an IARC Postdoctoral Fellowship at the International Agency for Research on Cancer. The laboratory of R.C.F. is funded by a Core Programme Grant from the Medical Research Council (RG84369), this research was supported by the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014) and OCCAMS2 was funded by a Programme Grant from Cancer Research UK (RG81771/84119). The work was also partly funded by the Practical Research Project for Innovative Cancer Control from the Japan Agency for Medical Research and Development (AMED) (JP20ck0106547h0001 to T.S.). A.M.G. and N.H were supported by the Intramural Research Program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health. L.B.A is an Abeloff V Scholar and is supported by an Alfred P. Sloan Research Fellowship. Research at UC San Diego was also supported by a Packard Fellowship for Science and Engineering to L.B.A.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approvals were first obtained from each Local Research Ethics Committee and Federal Ethics Committee when applicable, as well as from the IARC Ethics Committee (IRB number: IEC Project 17-10)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
This article is dedicated to the memory of Eleanor Wilde
Data Availability
Whole genome sequencing data and patient metadata are deposited in the European Genome 715 Phenome Archive (EGA) associated with study EGAS00001002725. BAM files for all cases included in the final analysis were deposited in dataset EGAD00001006868, and patient metadata in dataset EGAD00001006732. All other data is provided in the accompanying Supplementary Tables.
